Brown eyes are more likely to develop iris melanoma

Article

Patients with brown irises are most likely to develop melanomas.

Patients with brown irises are most likely to develop melanomas, according to recent study results published in the Archives of Ophthalmology.

The investigation, led by Dr Samira Khan, New York University School of Medicine, New York, USA, conducted a retrospective chart review on 131 iris melanoma patients from eight eye cancer centres across six countries.

Internet-assisted multicentre, privacy-protected on-line data entry was possible due to the creation of a computer program. Patient and tumour characteristics, ocular and angle abnormalities, management, histopathology and outcomes were among the factors included in the statistical analysis.

Of the patients studied, 65.6% had brown irises, 62.2% had blue-grey, 29.1% had green-hazel, 9.9% had amelanotic and 6.9% had multicoloured irises.

Patients experienced a variety of disorders including iritis, glaucoma, hyphaema and sector cataract. The results of high-frequency ultrasonograpy presented a largest mean tumour diameter of 4.9 mm, a mean maximum tumor thickness of 1.9 mm, angle blunting in 52% of patients, iris root disinsertion in 9% and posterior iris pigment epithelium displacement in 9%.

The American Joint Commission on Cancer-Internaional Union Against Cancer Classification was used to identify T1 tumours in 56% of patients, T2 tumours in 34%, T3 tumours in 2% and T4 tumours in 1%.

At five years the Kaplan-Meier analysis demonstrated a 10.7% risk of metastatic melanoma. The histopathologic grades were G1-spindle in 54% of patients, G2-mixed in 28%, G3-epithelioid in 5%, and undetermined in 13% of cell types.

The iris melanomas were commonly found in the inferior quadrants of patients with light irides. Angle blunting and spindle cell histopathology are linked to small and unifocal melanomas.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.